|
US7091181B2
(en)
|
1994-12-12 |
2006-08-15 |
Omeros Corporation |
Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
|
|
US6608060B1
(en)
|
1996-12-18 |
2003-08-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
|
US6673768B1
(en)
|
1997-10-16 |
2004-01-06 |
Board Of Regents, The University Of Texas System |
Transgenic animal models for cardiac hypertrophy and methods of use thereof (treating)
|
|
AU1924699A
(en)
|
1997-12-19 |
1999-07-12 |
Smithkline Beecham Corporation |
Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
|
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
|
WO1999061039A2
(en)
*
|
1998-05-22 |
1999-12-02 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel composition for modulating ischemic cell death
|
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
EP1277740A1
(en)
*
|
1998-06-12 |
2003-01-22 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
|
JP2002517486A
(ja)
*
|
1998-06-12 |
2002-06-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｐ３８のインヒビター
|
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
JP2002526482A
(ja)
*
|
1998-09-18 |
2002-08-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｐ３８のインヒビター
|
|
AR023659A1
(es)
|
1998-09-18 |
2002-09-04 |
Vertex Pharma |
Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
|
|
EP1261334A1
(en)
*
|
1998-10-20 |
2002-12-04 |
Omeros Corporation |
Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
|
|
DE69914357T2
(de)
|
1998-11-04 |
2004-11-11 |
Smithkline Beecham Corp. |
Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
CA2360934A1
(en)
|
1999-02-22 |
2000-08-31 |
Lin-Hua Zhang |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
|
JP2002539206A
(ja)
|
1999-03-12 |
2002-11-19 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤としての芳香族複素環化合物
|
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
|
JP2000281588A
(ja)
*
|
1999-03-30 |
2000-10-10 |
Sankyo Co Ltd |
ガンの予防又は治療薬及びそのスクリーニング方法
|
|
ES2260033T3
(es)
*
|
1999-07-02 |
2006-11-01 |
Stuart A. Lipton |
Uso de los inhibidores p38 mapk en efermadades oftalmicas.
|
|
CA2374737C
(en)
|
1999-07-09 |
2008-02-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
|
CZ20021743A3
(cs)
*
|
1999-10-21 |
2002-08-14 |
F. Hoffmann-La Roche Ag |
Bicyklické dusíkové heterocykly substituované alkylaminoskupinou jako inhibitory P38 proteinkinázy
|
|
AU776250B2
(en)
*
|
1999-10-21 |
2004-09-02 |
F. Hoffmann-La Roche Ag |
Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
|
|
JP2003514900A
(ja)
*
|
1999-11-23 |
2003-04-22 |
スミスクライン・ビーチャム・コーポレイション |
ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
|
|
US6759410B1
(en)
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
|
EP1233950B1
(en)
|
1999-11-23 |
2005-10-05 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
|
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
AU2001247700A1
(en)
*
|
2000-03-22 |
2001-10-03 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
|
JP4993838B2
(ja)
*
|
2000-08-11 |
2012-08-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｐ３８のインヒビターとしてのピリジン誘導体
|
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
|
CN100525768C
(zh)
|
2000-10-23 |
2009-08-12 |
史密丝克莱恩比彻姆公司 |
新化合物
|
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6867300B2
(en)
*
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
JP2004521892A
(ja)
|
2000-12-20 |
2004-07-22 |
メルク エンド カムパニー インコーポレーテッド |
（ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
|
|
DE60206363T2
(de)
*
|
2001-02-12 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
6-substituierte pyridopyrimidine
|
|
GB0112348D0
(en)
*
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
GB2375771A
(en)
*
|
2001-05-24 |
2002-11-27 |
Univ Leeds |
Decellularisation of tissue implant material
|
|
ATE415162T1
(de)
*
|
2001-06-11 |
2008-12-15 |
Vertex Pharma |
Isochinolin-inhibitoren von p38
|
|
US7005669B1
(en)
|
2001-08-02 |
2006-02-28 |
Ultradots, Inc. |
Quantum dots, nanocomposite materials with quantum dots, devices with quantum dots, and related fabrication methods
|
|
US20030066998A1
(en)
|
2001-08-02 |
2003-04-10 |
Lee Howard Wing Hoon |
Quantum dots of Group IV semiconductor materials
|
|
US6819845B2
(en)
|
2001-08-02 |
2004-11-16 |
Ultradots, Inc. |
Optical devices with engineered nonlinear nanocomposite materials
|
|
US6710366B1
(en)
|
2001-08-02 |
2004-03-23 |
Ultradots, Inc. |
Nanocomposite materials with engineered properties
|
|
US6794265B2
(en)
|
2001-08-02 |
2004-09-21 |
Ultradots, Inc. |
Methods of forming quantum dots of Group IV semiconductor materials
|
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124938D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP1476840A4
(en)
*
|
2002-01-11 |
2007-05-09 |
Vertex Pharma |
CRYSTALLINE STRUCTURES OF JNK INHIBITION COMPLEXES AND BINDING POCKETS THEREOF
|
|
AU2003209321A1
(en)
*
|
2002-01-18 |
2003-07-30 |
Pharmacia Corporation |
Substituted pyridazinones as inhibitors of p38
|
|
ATE375980T1
(de)
|
2002-02-12 |
2007-11-15 |
Smithkline Beecham Corp |
Nicotinamide und deren verwendung als p38 inhibitoren
|
|
EP1480973B1
(en)
|
2002-02-25 |
2008-02-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
US20040034083A1
(en)
*
|
2002-04-18 |
2004-02-19 |
Stephenson Diane T. |
Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
|
|
KR20040103972A
(ko)
|
2002-04-19 |
2004-12-09 |
스미스클라인 비참 코포레이션 |
신규 화합물
|
|
PT1497019E
(pt)
*
|
2002-04-23 |
2015-09-10 |
Bristol Myers Squibb Co |
Compostos de pirrolotriazina anilina úteis como inibidores de quinase
|
|
US7388009B2
(en)
*
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
|
TW200306841A
(en)
*
|
2002-04-23 |
2003-12-01 |
Bristol Myers Squibb Co |
Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
|
|
TW200400034A
(en)
*
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
|
CA2486183C
(en)
*
|
2002-05-23 |
2012-01-10 |
Cytopia Pty Ltd. |
Protein kinase inhibitors
|
|
ES2278170T3
(es)
|
2002-07-09 |
2007-08-01 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
|
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
|
BR0315942A
(pt)
|
2002-11-27 |
2005-10-04 |
Dmi Biosciences Inc |
Tratamento de doenças e condições mediadas pelo aumento de fosforilação
|
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
EP2385041B1
(en)
*
|
2003-05-01 |
2013-09-18 |
Bristol-Myers Squibb Company |
Pyrazole-amine compounds useful as kinase inhibitors
|
|
CA2526285A1
(en)
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Inhibitors of p38 and methods of using the same
|
|
US7652044B2
(en)
*
|
2003-06-03 |
2010-01-26 |
Novartis A.G. |
P-38 inhibitors
|
|
PL2298743T3
(pl)
|
2003-06-26 |
2013-02-28 |
Novartis Ag |
Inhibitory kinaz P38 na bazie 5-członowych heterocykli
|
|
WO2005007632A1
(en)
*
|
2003-07-18 |
2005-01-27 |
Pharmacia Corporation |
Substituted pyridazinones as inhibitors of p38
|
|
EP1687284B1
(en)
*
|
2003-07-25 |
2008-10-29 |
Novartis AG |
p-38 KINASE INHIBITORS
|
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
|
US7419978B2
(en)
*
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
|
CA2545422C
(en)
|
2003-12-03 |
2015-06-02 |
Cytopia Research Pty Ltd |
Tubulin inhibitors
|
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
WO2006010082A1
(en)
|
2004-07-08 |
2006-01-26 |
Arqule, Inc. |
1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
|
|
US7504521B2
(en)
*
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
WO2006021848A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Ranbaxy Laboratories Limited |
Anti-inflammatory agents
|
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
|
EP2258704A1
(en)
|
2004-10-19 |
2010-12-08 |
ArQule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
US20060178388A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
|
US20080096905A1
(en)
|
2005-03-25 |
2008-04-24 |
Glaxo Group Limited |
Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
|
|
PE20061193A1
(es)
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
|
US7423042B2
(en)
|
2005-03-25 |
2008-09-09 |
Glaxo Group Limited |
Compounds
|
|
MY145343A
(en)
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
|
US20060235020A1
(en)
*
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
|
US7473784B2
(en)
*
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
|
CA2618614A1
(en)
*
|
2005-08-12 |
2007-02-22 |
Merck & Co., Inc. |
Heterobicyclic compounds useful as p38 kinase inhibiting agents
|
|
CA2627497C
(en)
|
2005-10-28 |
2014-10-14 |
Takeda Pharmaceutical Company Limited |
Heterocyclic amide compound and use thereof
|
|
KR20080107408A
(ko)
*
|
2006-03-07 |
2008-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
|
|
EP2083816A2
(en)
*
|
2006-10-27 |
2009-08-05 |
Brystol-Myers Squibb Company |
Heterocyclic amide compounds useful as kinase inhibitors
|
|
US7943617B2
(en)
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
|
US20100104536A1
(en)
*
|
2007-03-20 |
2010-04-29 |
Indravadan Ambalal Modi |
P38 inhibitors
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
EP2108641A1
(en)
*
|
2008-04-11 |
2009-10-14 |
Laboratorios Almirall, S.A. |
New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
CN102131805A
(zh)
|
2008-06-20 |
2011-07-20 |
百时美施贵宝公司 |
用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
|
|
WO2009155389A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
|
WO2010038428A1
(ja)
*
|
2008-09-30 |
2010-04-08 |
武田薬品工業株式会社 |
タキサン系抗がん剤の置き換え薬
|
|
US8450363B2
(en)
|
2009-02-06 |
2013-05-28 |
Elan Pharmaceuticals, Inc. |
Inhibitors of Jun N-terminal kinase
|
|
GB0902648D0
(en)
|
2009-02-17 |
2009-04-01 |
Argenta Discovery Ltd |
Pharmaceutical compounds and compositions
|
|
GB0908317D0
(en)
*
|
2009-05-14 |
2009-06-24 |
Argenta Discovery Ltd |
Pharmaceutical compounds and compositions
|
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
|
DK3081568T3
(da)
*
|
2011-05-09 |
2020-02-24 |
Eip Pharma Llc |
Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom
|
|
ES2897740T3
(es)
|
2011-12-28 |
2022-03-02 |
Kyoto Prefectural Public Univ Corp |
Normalización del cultivo de células endoteliales de la córnea
|
|
CN103772392A
(zh)
*
|
2012-10-23 |
2014-05-07 |
杨子娇 |
一类治疗房角狭窄的化合物及其用途
|
|
WO2015072580A1
(ja)
|
2013-11-14 |
2015-05-21 |
学校法人同志社 |
細胞増殖促進または細胞障害抑制による角膜内皮治療薬
|
|
EP3166610B1
(en)
|
2014-07-09 |
2022-11-02 |
Eip Pharma, LLC |
Methods for treating neurologic disorders
|
|
EP3368052B1
(en)
|
2015-10-27 |
2021-12-08 |
Children's Hospital Medical Center |
Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and genetic manipulation
|
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
|
US11466008B2
(en)
|
2017-09-18 |
2022-10-11 |
Eip Pharma, Llc |
Co-crystals of neflamapimod (VX-745)
|
|
BR112020006677A2
(pt)
|
2017-10-05 |
2020-10-06 |
Fulcrum Therapeutics, Inc. |
uso de inibidores p38 para reduzir a expressão de dux4
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
BR112020018094A2
(pt)
|
2018-03-08 |
2020-12-22 |
Incyte Corporation |
Compostos de aminopirazina diol como inibidores de pi3k-¿
|
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
|
WO2020108659A1
(zh)
|
2018-11-30 |
2020-06-04 |
上海医药集团股份有限公司 |
含氮杂环类化合物及其组合物、制备方法和应用
|